#USA #Sydney #TNBC #Kazia Therapeutics #Paxalisib

Overview of Kazia Therapeutics’ Breakthrough Results

Kazia Therapeutics Limited, a biotechnology company specializing in oncology, has announced remarkable findings from its latest clinical trial involving paxalisib, a drug being developed to combat advanced triple-negative breast cancer (TNBC). In this small, initial trial, all six patients demonstrated clinical benefits, marking a significant milestone in the fight against one of the most challenging cancer types.

Clinical Trial Details

The study found that five out of the six evaluable patients achieved a measurable response in tumor reduction—defined as a decrease of 30% or more. This group’s results included one instance of complete response and four partial responses, leading to an impressive 83% overall response rate. Furthermore, the remaining patient maintained stable disease post-treatment. All participants endorsed the favorable profile of oral dosing, with strikingly low incidences of serious side effects, a common concern with many cancer treatments.

Dr. John Friend, the CEO of Kazia Therapeutics, emphasized the significance of these results. Given that TNBC is notoriously difficult to treat, with only 12% of patients surviving five years after diagnosis, the data shines a light on the potential benefits of paxalisib.

Immune Response and Tumor Reduction

One of the most noteworthy findings of this trial was the improvements seen in patients’ immune responses. The treatment not only led to substantial reductions in tumor burden, but it also addressed the depletion of T cells, which play a pivotal role in the immune response against cancer. Specifically, reductions in terminally exhausted T cells—a type of immune cell that has lost its ability to fight cancer—were observed, indicating that paxalisib might be restoring immune functionality alongside reducing metastatic progression. In the assessed cohort, there was a median reduction of 51% in these exhausted T cells within approximately three weeks of treatment.

Extended Benefits and Ongoing Studies

Clinical responses were evident across various metastatic disease sites, such as the lungs, liver, bones, lymph nodes, and even the central nervous system. The preliminary findings suggest that the effects of paxalisib could be dual-pronged—addressing both the biological mechanisms behind treatment resistance and mitigating cancer metastasis.

Indeed, these results pave the way for further investigations. Kazia is currently engaged in a Phase 1b clinical trial that explores the use of paxalisib in combination with pembrolizumab and chemotherapy for advanced TNBC. The company anticipates completing the enrollment for this study by July 2027 with intermittent updates expected throughout 2026 and 2027.

Conclusion

As Kazia Therapeutics furthers its research and trials involving paxalisib, healthcare professionals and patients alike remain hopeful for innovative solutions against advanced TNBC. By demonstrating a 100% clinical benefit rate in this initial cohort, Kazia not only sheds light on a promising treatment but also underscores the vital role of fostering advancements in cancer therapeutics. With ongoing studies continuing to evaluate the efficacy and safety of paxalisib, the fight against one of cancer’s most formidable variants remains underway, offering a beacon of hope for those affected by TNBC.